We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Several pharmaceutical companies are working to find alternative drugs to treat COVID-19-associated mucormycosis in India amid concerns there might be a shortage of amphotericin B, reported Sputnik.